Peggy Scherle
Chief Scientific Officer · Prelude Therapeutics Inc
Individual
- 2026
- Feb 5, 2026
- 1
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Peggy Scherle files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $12.50M in PRLD purchases and sales in the last 12 months
- David P. Bonita - $12.50M in PRLD purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $10.00M in PRLD purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Peggy Scherle?
Peggy Scherle is a corporate insider, tracked as Chief Scientific Officer of Prelude Therapeutics Inc (PRLD). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Peggy Scherle last file a Form 4?
The only primary Form 4 on record is dated 5 February 2026.